AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Arimidex Observational: Reason for and Effect of Change From Tamoxifen
Completed
- Conditions
- First Posted Date
- 2005-11-01
- Last Posted Date
- 2007-10-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT00246961
- Locations
- 🇳🇱
Research Site, Zutphen, Netherlands
🇳🇱Research SIte, Dordrecht, Netherlands
Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2011-08-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 95
- Registration Number
- NCT00244621
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
A Comparison of the Control of Asthma Provided by Symbicort® Turbuhaler® Versus Symbicort® Turbuhaler® Plus Pulmicort® Turbuhaler® Plus Terbutaline Turbuhaler®
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT00244608
- Locations
- 🇬🇧
Research Site, Southampton, United Kingdom
Efficacy, Safety, & Pharmacokinetics of Candesartan Cilexetil in Hypertensive Paediatric Subjects 6 to < 17 Years of Age
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2009-12-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 235
- Registration Number
- NCT00244595
- Locations
- 🇸🇰
Research Site, Trnava, Slovakia
Atacand Dose Range Finding Study in Pediatric Subjects 6 to <17 Years of Age
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2007-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 238
- Registration Number
- NCT00244634
- Locations
- 🇸🇰
Research Site, Trnava, Slovakia
HEARD (Long Term) Study - Histology of the Esophagus in Acid-Related Disease
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-25
- Last Posted Date
- 2009-03-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 350
- Registration Number
- NCT00243724
- Locations
- 🇨🇦
Research Site, Quebec, Canada
The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer
Phase 1
Completed
- Conditions
- First Posted Date
- 2005-10-24
- Last Posted Date
- 2013-10-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 19
- Registration Number
- NCT00243347
- Locations
- 🇪🇸
Research Site, Barcelona, Spain
IRESSA in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-10-21
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 47
- Registration Number
- NCT00242749
- Locations
- 🇪🇸
Research Site, Santander, Spain
IRESSA™ In Combo With Xeloda™ in Advanced Colorectal Cancer Patients After 1st-Line Chemo Failure
Phase 1
Completed
- Conditions
- First Posted Date
- 2005-10-21
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT00242788
- Locations
- 🇪🇸
Research Site, Zaragoza, Spain
Iressa vs Best Supportive Care - 2nd/3rd Line Survival Study
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-21
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1692
- Registration Number
- NCT00242801
- Locations
- 🇻🇪
Research Site, Various Cities, Venezuela
© Copyright 2024. All Rights Reserved by MedPath